Zacks Research Issues Positive Forecast for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities researchers at Zacks Research increased their Q4 2026 earnings per share (EPS) estimates for shares of Prestige Consumer Healthcare in a note issued to investors on Tuesday, November 25th. Zacks Research analyst Team now anticipates that the company will earn $1.53 per share for the quarter, up from their previous estimate of $1.37. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q1 2027 earnings at $1.23 EPS, Q2 2027 earnings at $1.14 EPS, Q3 2027 earnings at $1.20 EPS and FY2028 earnings at $5.19 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. During the same quarter last year, the company earned $1.09 EPS. Prestige Consumer Healthcare’s revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS.

A number of other equities research analysts have also recently issued reports on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Wednesday, October 8th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective on the stock in a research note on Wednesday, September 24th. Oppenheimer cut their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday, October 21st. Canaccord Genuity Group decreased their price target on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Jefferies Financial Group reduced their price objective on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research note on Monday, October 27th. Four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.33.

Prestige Consumer Healthcare Stock Up 1.1%

Shares of NYSE PBH opened at $59.67 on Thursday. The stock has a market cap of $2.87 billion, a PE ratio of 14.01, a PEG ratio of 1.93 and a beta of 0.41. The business has a fifty day moving average of $61.46 and a two-hundred day moving average of $71.10. Prestige Consumer Healthcare has a 52-week low of $57.25 and a 52-week high of $90.04. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.99 and a current ratio of 4.38.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Private Wealth Group LLC lifted its stake in shares of Prestige Consumer Healthcare by 142.8% during the third quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after acquiring an additional 647 shares during the period. CIBC Bancorp USA Inc. bought a new stake in Prestige Consumer Healthcare during the 3rd quarter worth about $329,000. Danske Bank A S bought a new stake in Prestige Consumer Healthcare during the 3rd quarter worth about $37,000. Advisory Services Network LLC acquired a new position in Prestige Consumer Healthcare during the 3rd quarter valued at about $181,000. Finally, Morningstar Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare in the 3rd quarter valued at about $956,000. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.